$GILD buys out rights to early-stage $JNCE cancer drug as part of ongoing efforts to beef up its cancer drug pipeline.
Gilead Sciences Inc. will pay $67 million for the remaining rights to a cancer immunotherapy drug from partner Jounce Therapeutics Inc., a move to strengthen the Foster City-based drug maker's pipeline of potential cancer drugs.
GS-1811 is designed to selectively deplete immune system-suppressing T regulatory cells that infiltrate the area in and around tumors, giving the body's immune system a better chance at fighting off the cancer. "GS-1811, with its potential new pathway of activating the immune system, gives us the opportunity to potentially change the standard of care with a treatment works from inside cancerous cells to shrink solid tumors," said Dr.Richard Murray
Australia Latest News, Australia Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Jounce stock bounces more than 70% after Gilead acquires immunotherapy drugJounce Therapeutics Inc. shares jumped more than 70% in after-hours trading Tuesday, following an announcement that Gilead Sciences Inc. would completely...
Read more »
Gilead buys out rights to cancer therapy from Jounce for $67 mlnGilead Sciences will buy all the remaining rights for an experimental cancer therapy, GS-1811, from Jounce Therapeutics for $67 million, the drugmaker said on Tuesday.
Read more »
Gilead buys remaining rights to cancer immunotherapy drug from partner Jounce - San Francisco Business Times$GILD buys out rights to early-stage $JNCE cancer drug as part of ongoing efforts to beef up its cancer drug pipeline.
Read more »
Year in Review: Five notable tech bills passed this year as Silicon Valley faces populist backlashCongress was able to pass a few small yet significant pieces of technology-related legislation amid growing populist hostility toward Big Tech from the Left over profit margins and the Right over culture war issues.
Read more »
S.F. grocery delivery giant Instacart trims valuation - Silicon Valley Business JournalInstacart cut its meaty valuation back in March. Here's how much it's just trimmed it again. bayarea technews
Read more »